Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Alzamend Neuro Inc (ALZN)

Alzamend Neuro Inc (ALZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital PR Newswire - Tue Apr 7, 7:00AM CDT

ATLANTA , April 7, 2026 /PRNewswire/ -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (" Alzamend "), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment...

ALZN : 1.1100 (-0.89%)
Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions PR Newswire - Thu Mar 26, 7:00AM CDT

ATLANTA , March 26, 2026 /PRNewswire/ -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (" Alzamend "), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment...

ALZN : 1.1100 (-0.89%)
Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital PR Newswire - Mon Mar 16, 7:00AM CDT

ATLANTA , March 16, 2026 /PRNewswire/ --  Alzamend Neuro, Inc. (Nasdaq: ALZN) (" Alzamend "), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment...

ALZN : 1.1100 (-0.89%)
Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital PR Newswire - Wed Nov 19, 2025

ATLANTA , Nov. 19, 2025 /PRNewswire/ --  Alzamend Neuro, Inc. (Nasdaq: ALZN) (" Alzamend "), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment...

ALZN : 1.1100 (-0.89%)
Alzamend Neuro Issues New Common Stock Shares Tipranks - Fri Oct 10, 2025

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Alzamend...

ALZN : 1.1100 (-0.89%)
Alzamend Neuro to Present at the 2025 Military Health System Research Symposium GlobeNewswire - Mon Jul 28, 2025

Session Topic is the I nnovation and Current Directions in Military Suicide Prevention, Research, and Programs Presentation Title is Quantitate Differences in Lithium Brain-to-Plasma Exposure in...

ALZN : 1.1100 (-0.89%)
Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs GlobeNewswire - Wed Jul 23, 2025

During the year ended April 30, 2025, net cash provided by financing activities was $10.4 million Stockholder equity of $4.0 million at April 30, 2025, including $3.9 million of cash In May 2025,...

ALZN : 1.1100 (-0.89%)
Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule GlobeNewswire - Mon Jun 16, 2025

ALZN : 1.1100 (-0.89%)
Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital GlobeNewswire - Thu May 29, 2025

ALZN : 1.1100 (-0.89%)
Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital GlobeNewswire - Mon May 19, 2025

ALZN : 1.1100 (-0.89%)

Barchart Exclusives

2 Option Trade Ideas To Consider This Tuesday Barchart - 6 minutes ago
Today, we are using the stock screener to find stocks with a Buy rating and then looking at a couple of bullish option trade ideas. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.